These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 12042841)

  • 1. HGS drug flop latest genomics setback.
    Reid B
    Nat Biotechnol; 2002 Jun; 20(6):533. PubMed ID: 12042841
    [No Abstract]   [Full Text] [Related]  

  • 2. Free genome databases finally defeat Celera.
    Marris E
    Nature; 2005 May; 435(7038):6. PubMed ID: 15874985
    [No Abstract]   [Full Text] [Related]  

  • 3. Prescription for an ailing pharmaceutical industry.
    Demain AL
    Nat Biotechnol; 2002 Apr; 20(4):331. PubMed ID: 11923826
    [No Abstract]   [Full Text] [Related]  

  • 4. Rediscovering plant-based drugs.
    Littleton J; Falcone D; Davies HM
    Nat Biotechnol; 2003 Aug; 21(8):843-4. PubMed ID: 12894188
    [No Abstract]   [Full Text] [Related]  

  • 5. How many genomics targets can a portfolio afford?
    Betz UA
    Drug Discov Today; 2005 Aug; 10(15):1057-63. PubMed ID: 16055022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder bows out as genomic firm slashes workforce.
    Wadman M
    Nature; 2004 Apr; 428(6982):456. PubMed ID: 15057797
    [No Abstract]   [Full Text] [Related]  

  • 7. A rollercoaster ride.
    Jacobs T
    Nat Biotechnol; 2006 Mar; 24(3):284. PubMed ID: 16525390
    [No Abstract]   [Full Text] [Related]  

  • 8. Rising costs hold up drug discovery.
    Miller HI
    Nature; 1998 Oct; 395(6705):835. PubMed ID: 9804407
    [No Abstract]   [Full Text] [Related]  

  • 9. Curagen sets precedent in post genomics era.
    Fletcher L
    Nat Biotechnol; 2001 Mar; 19(3):186-7. PubMed ID: 11231517
    [No Abstract]   [Full Text] [Related]  

  • 10. Biotech blockbusters consolidate markets.
    Lawrence S
    Nat Biotechnol; 2006 Dec; 24(12):1466. PubMed ID: 17160033
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyseq-Variagenics merger signals end of the line.
    Hodgson J
    Nat Biotechnol; 2003 Jan; 21(1):5. PubMed ID: 12511895
    [No Abstract]   [Full Text] [Related]  

  • 12. Genomics. After the gold rush: gene firms reinvent themselves.
    Gura T
    Science; 2002 Sep; 297(5589):1982-4. PubMed ID: 12242421
    [No Abstract]   [Full Text] [Related]  

  • 13. Spinning the wheel on ImClone.
    Varchaver N
    Fortune; 2003 Apr; 147(8):123-5. PubMed ID: 12728651
    [No Abstract]   [Full Text] [Related]  

  • 14. Can complexity be commercialized?
    Mack GS
    Nat Biotechnol; 2004 Oct; 22(10):1223-9. PubMed ID: 15470456
    [No Abstract]   [Full Text] [Related]  

  • 15. The biotech drug market.
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1496. PubMed ID: 15583645
    [No Abstract]   [Full Text] [Related]  

  • 16. Biotechnology in Ireland: hard work, money and the brain gain.
    O'Neill MF
    Drug Discov Today; 2007 Feb; 12(3-4):108-11. PubMed ID: 17275730
    [No Abstract]   [Full Text] [Related]  

  • 17. Biotech industry tries to recover from 2-year lull.
    Brower V
    J Natl Cancer Inst; 2003 Mar; 95(5):348-9. PubMed ID: 12618496
    [No Abstract]   [Full Text] [Related]  

  • 18. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of the "new science" of genomics.
    Coile RC
    J Healthc Manag; 2001; 46(6):365-8. PubMed ID: 11729566
    [No Abstract]   [Full Text] [Related]  

  • 20. Post-genome, Celera now shoots for profits.
    O'Keefe B
    Fortune; 2001 Feb; 143(4):226. PubMed ID: 11272265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.